<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Treat Res Commun</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Treat Res Commun</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Cancer treatment and research communications</journal-title></journal-title-group><issn pub-type="epub">2468-2942</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10528526</article-id><article-id pub-id-type="pmcid-ver">PMC10528526.1</article-id><article-id pub-id-type="pmcaid">10528526</article-id><article-id pub-id-type="pmcaiid">10528526</article-id><article-id pub-id-type="manuscript-id">NIHMS1928305</article-id><article-id pub-id-type="pmid">37352588</article-id><article-id pub-id-type="doi">10.1016/j.ctarc.2023.100730</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1928305</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1928305</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Carroll</surname><given-names initials="NM">Nikki M.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eisenstein</surname><given-names initials="J">Jennifer</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burnett-Hartman</surname><given-names initials="AN">Andrea N.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Greenlee</surname><given-names initials="RT">Robert T.</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Honda</surname><given-names initials="SA">Stacey A.</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neslund-Dudas</surname><given-names initials="CM">Christine M.</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rendle</surname><given-names initials="KA">Katharine A.</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vachani</surname><given-names initials="A">Anil</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ritzwoller</surname><given-names initials="DP">Debra P.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA</aff><aff id="A2"><label>b</label>Colorado Permanente Medical Group, Kaiser Permanente Colorado, Denver, CO, USA</aff><aff id="A3"><label>c</label>Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA</aff><aff id="A4"><label>d</label>Marshfield Clinic Research Institute, Marshfield, WI, USA</aff><aff id="A5"><label>e</label>Hawaii Permanente Medical Group and Center for Integrated Healthcare Research, Kaiser Permanente Hawaii, Honolulu, HI, USA</aff><aff id="A6"><label>f</label>Henry Ford Health and Henry Ford Cancer Institute, Detroit, MI, USA</aff><aff id="A7"><label>g</label>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author at: Institute for Health Research, Kaiser Permanente Colorado. 2550 S Parker Road, Suite 200 Aurora. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="@NikkiMCarroll1" ext-link-type="uri">@NikkiMCarroll1</ext-link>, CO 80014, USA. <email>nikki.m.carroll@kp.org</email> (N.M. Carroll).</corresp></author-notes><pub-date pub-type="ppub"><year>2023</year></pub-date><pub-date pub-type="epub"><day>14</day><month>6</month><year>2023</year></pub-date><volume>36</volume><issue-id pub-id-type="pmc-issue-id">446078</issue-id><fpage>100730</fpage><lpage>100730</lpage><pub-history><event event-type="nihms-submitted"><date><day>31</day><month>08</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>27</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 15:25:31.883"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1928305.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction/background:</title><p id="P1">Systemic treatment for advanced non-small cell lung cancer (NSCLC) is shifting from platinum-based chemotherapy to immunotherapy and targeted therapies associated with improved survival in clinical trials. As new therapies are approved for use, examining variations in use for treating patients in community practice can generate additional evidence as to the magnitude of their benefit.</p></sec><sec id="S2"><title>Patients and methods:</title><p id="P2">We identified 1,442 patients diagnosed with de novo stage IV NSCLC between 3/1/2012 and 12/31/2020. Patient characteristics and treatment patterns are described overall and by type of first- and second-line systemic therapy received. Prevalence ratios estimate the association of patient and tumor characteristics with receipt of first-line therapy.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Within 180 days of diagnosis, 949 (66%) patients received first-line systemic therapy, increasing from 53% in 2012 to 71% in 2020 (<italic toggle="yes">p</italic> = 0.0004). The proportion of patients receiving first-line immunotherapy+/&#8722;chemotherapy (IMO) increased from 14%&#8211;66% (<italic toggle="yes">p</italic>&lt;0.0001). Overall, 380 (26%) patients received both first- and second-line treatment, varying by year between 16%&#8211;36% (<italic toggle="yes">p</italic> = 0.18). The proportion of patients receiving second-line IMO increased from 13%&#8211;37% (<italic toggle="yes">p</italic>&lt;0.0001). Older age and current smoking status were inversely associated with receipt of first-line therapy. Higher BMI, receipt of radiation, and diagnosis year were positively associated with receipt of first-line therapy. No association was found for race, ethnicity, or socioeconomic status.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">The proportion of advanced NSCLC patients receiving first- and second-line treatment increased over time, particularly for IMO treatments. Additional research is needed to better understand the impact of these therapies on patient outcomes, including short-term, long-term, and financial toxicities.</p></sec><sec id="S5"><title>Microabstract:</title><p id="P5">Systemic treatment for non-small cell lung cancer (NSCLC) is shifting from platinum-based therapies to immunotherapy and targeted therapies. Using de novo stage IV NSCLC patients identified from 4 healthcare systems, we examine trends in systemic therapy. We saw an increase in the portion of patients receiving any systemic therapy and a sharp increase in the proportion of patients receiving immunotherapy.</p></sec></abstract><kwd-group><kwd>Non-small cell lung cancer</kwd><kwd>Treatment patterns</kwd><kwd>Immunotherapy</kwd><kwd>Targeted therapy</kwd><kwd>First-line treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S6"><title>Introduction</title><p id="P6">Despite an increase in survival among individuals diagnosed with lung cancer between 2009 and 2016, lung cancer remains the leading cause of cancer deaths with an estimated 131,880 deaths in 2021 [<xref rid="R1" ref-type="bibr">1</xref>]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers [<xref rid="R2" ref-type="bibr">2</xref>] and patients diagnosed with metastatic lung cancer account for approximately 57% of all lung cancers [<xref rid="R1" ref-type="bibr">1</xref>]. Platinum-based cytotoxic chemotherapy has been the standard of care for advanced NSCLC for over 30 years; however, the development of immunotherapies and targeted therapies within the past 15 years have been associated with improved survival in clinical trials, [<xref rid="R2" ref-type="bibr">2</xref>&#8211;<xref rid="R9" ref-type="bibr">9</xref>] resulting in a guideline shift from the platinum-based standard of care to include these novel therapies [<xref rid="R10" ref-type="bibr">10</xref>&#8211;<xref rid="R16" ref-type="bibr">16</xref>].</p><p id="P7">Immune checkpoint inhibitors establish or enhance effective immune responses toward a tumor and block certain proteins such as the programmed death-1 (PD-1), Programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) while tyrosine kinas inhibitor therapies have been approved to target drive mutations such as EGFR, ALK, ROS1, and BRAF [<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R11" ref-type="bibr">11</xref>&#8211;<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R16" ref-type="bibr">16</xref>&#8211;<xref rid="R18" ref-type="bibr">18</xref>]. As more emerging therapies are approved for use, it is important to understand variations in use for treating patients in community practice. For example, it is unknown if treatment rates are similar in younger patients vs. older patients or for those receiving care in integrated healthcare delivery systems vs. other healthcare models. Evaluating the uptake and use of recently approved systemic therapy regimens in community settings is critical to generate additional evidence as to the magnitude of benefit of treatments and to further the generalizability of trial findings [<xref rid="R19" ref-type="bibr">19</xref>]. Relative to standard platinum-based regimens, most of these novel treatments are associated with fewer toxicities, but the cost is substantially more.</p><p id="P8">This study aims to fill the gap in the literature on patterns of first- and second-line systemic therapy treatment administered to patients diagnosed with advanced NSCLC in real-world, community settings. Using electronic health record (EHR) data from four health systems in the Population-based Research to Optimize the Screening Process (PROSPR)-Lung Consortium, we examine the variation in the type of first- and second-line systemic therapy administered over time and assess the factors associated with receipt of first-line systemic therapy.</p></sec><sec id="S7"><title>Patients and methods</title><sec id="S8"><title>Study setting and data sources</title><p id="P9">The PROSPR-Lung Common Data Model (CDM) contains population and health-system based data associated with 5 diverse healthcare systems: Henry Ford Health, Kaiser Permanente Colorado, Kaiser Permanente Hawaii, Marshfield Clinic Health System, and the University of Pennsylvania Health System [<xref rid="R20" ref-type="bibr">20</xref>]. As described in detail elsewhere, [<xref rid="R21" ref-type="bibr">21</xref>&#8211;<xref rid="R23" ref-type="bibr">23</xref>] the PROSPR-Lung CDM is a standardized resource containing data derived from each healthcare system&#8217;s EHR including: patient demographics, smoking status, diagnoses, procedures, pharmacy, and infusions. Census-based measures of socioeconomic status (SES) were captured by mapping the patient&#8217;s residential address to census tract data using geocoding software. The PROSPR-Lung CDM includes cancer registry data collected in a manner consistent with the North American Association of Central Cancer Registries standards [<xref rid="R24" ref-type="bibr">24</xref>].</p></sec><sec id="S29"><title>Study population</title><p id="P11">The study population for this retrospective analysis included patients from 4 of the 5 PROSPR-Lung healthcare systems. One healthcare system was excluded due to lack of data on infused therapies. Patients between the ages of 35 and 89 diagnosed with de novo Stage IV NSCLC between March 1, 2012, and December 31, 2020 were included. Patients had to be either an enrolled member in the healthcare system at the time of diagnosis and/or have a recorded primary care encounter in the 3 years prior to their lung cancer diagnosis. All patients had to have survived at least 30 days post diagnosis. Patients in enrollment-based healthcare systems were followed until the first of dis-enrollment from the health system, death, or December 31, 2021 while patients in primary-care based healthcare systems were followed until the last encounter date noted within the EHR, death, or December 31, 2021.</p><p id="P12">We collected information on sex, race, ethnicity, tumor characteristics, and first- and second-line systemic treatment. We identified the closest recorded cigarette smoking status and body mass index (BMI) (kg/m<sup>2</sup>) prior to lung cancer diagnosis. Smoking status was categorized as current, former, never, and unknown. Comorbidity burden was estimated using the Deyo adaptation of the Charlson Comorbidity Index (CCI) [<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]. SES was assessed by the Yost index, an area-level composite measure [<xref rid="R27" ref-type="bibr">27</xref>].</p></sec><sec id="S9"><title>Systemic therapy and line of therapy definitions</title><p id="P13">Systemic therapy was defined as any cytotoxic chemotherapy, immunotherapy, or molecularly targeted therapy administered to patients in the study cohort. Receipt of first-line systemic therapy was defined as the receipt of at least one systemic therapy agent within 180 days of diagnosis [<xref rid="R28" ref-type="bibr">28</xref>&#8211;<xref rid="R31" ref-type="bibr">31</xref>]. We used a previously developed algorithm that identifies specific regimens in the entire course of systemic therapy treatment [<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]. The algorithm identifies the first systemic therapy agent administered. Additional systemic therapy agents received within 10 days of the first agent are considered to be components of the same regimen. The first regimen was defined as first-line systemic therapy. Changes in receipt of systemic therapy were then evaluated longitudinally up to 1 year after diagnosis. The first change in systemic therapy agents indicates the second line of systemic therapy. The discontinuation of a single agent from a regimen was not considered a change in line of therapy.</p><p id="P14">Systemic therapy regimens were grouped into three categories: &#8220;Chemo-only&#8221; contains regimens consisting of cytotoxic chemotherapy agents with no immunotherapy or targeted therapy agents; &#8220;IMO&#8221; contains regimens consisting of immunotherapy agents with or without a cytotoxic chemotherapy agent; and &#8220;Targeted&#8221; contains regimens consisting of targeted therapy agents. IMO encompasses all immune checkpoint inhibitors and protein-antibodies made to treat cancer. While some immunotherapy agents have mechanisms that target specific molecules, we categorized these drugs as immunotherapy since they can be considered antibodies that include compounds that have relation to the immune system. <xref rid="SD1" ref-type="supplementary-material">Supplemental Table 1</xref> shows categorization of all systemic therapies observed in this study.</p></sec><sec id="S10"><title>Statistical analysis</title><p id="P15">The primary outcome was the proportion of advanced NSCLC patients receiving first-line and second-line systemic therapy. We calculated the percentages of patients who received first-line and second-line systemic therapy separately by stage, morphology, receipt of other first course therapy modalities, year of diagnosis, sex, race and ethnicity, age at diagnosis, smoking status, healthcare system, comorbidity burden, BMI, and SES. Trends in the receipt of systemic therapy over time were evaluated using the Cochran-Armitage trend test. Differences in the receipt and distribution of type of systemic therapy received by age group were evaluated by the chi-square test.</p><p id="P16">The strength of association between patient (age at diagnosis, sex, race and ethnicity, smoking status, comorbidity burden, BMI, socioeconomic status, year of diagnosis, and healthcare system) and tumor factors (stage, histology, and receipt of other first course therapy modalities) with the receipt of any first-line systemic therapy was evaluated with marginal prevalence ratios (PRs) and 95% confidence intervals (CIs) using log-binomial regression models with a robust sandwich estimator. We estimated unadjusted PRs and PRs mutually adjusted for each patient and tumor factor specified above. Data on BMI and the Yost Index was missing for 3% of the study population. To address missing data, we used multiple imputation by chained equations (MICE) [<xref rid="R33" ref-type="bibr">33</xref>].</p><p id="P17">All analyses were performed using SAS<sup>&#174;</sup> Software version 9.4M6 (SAS Institute Inc., Cary, North Carolina). All STROBE guidelines were followed. All p-values were two sided and a <italic toggle="yes">p</italic>&lt;0.05 was considered statistically significant. Study protocols and human subject protection considerations were reviewed and approved by the Institutional Review Board (IRB) at Kaiser Permanente Colorado, which is the IRB of record for PROSPR-Lung.</p></sec></sec><sec id="S11"><title>Results</title><p id="P18">Of 2148 patients diagnosed with de novo stage IV NSCLC between 3/1/2012 and 12/31/2020, 1442 met all inclusion criteria and survived at least 30 days past diagnosis (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Patients with non-squamous histology comprised 84% of the final cohort, 50% of the final cohort were female, 64% were non-Hispanic white adults, 12% were non-Hispanic black adults, and 35% were between the ages of 35 and 64 at the time of diagnosis (<xref rid="T1" ref-type="table">Table 1</xref>).</p><sec id="S12"><title>First-line systemic therapy</title><p id="P19">Overall, 949 (66%) patients received a first-line course of any systemic therapy type (<xref rid="T1" ref-type="table">Table 1</xref>), increasing from 53% in 2012 to 71% in 2020 (<xref rid="F2" ref-type="fig">Fig. 2</xref>; <italic toggle="yes">p</italic> = 0.01). The proportion of patients receiving Chemo-only decreased from 65% in 2012 to 12% in 2020 (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <italic toggle="yes">p</italic>&lt;0.0001). Patients receiving IMO increased from 14% in 2012 to 66% in 2020 (<italic toggle="yes">p</italic>&lt;0.0001). The proportion of patients receiving Targeted agents did not significantly vary over time starting at 14% in 2012 and ending at 22% in 2018 (<italic toggle="yes">p</italic> = 0.33).</p></sec><sec id="S13"><title>Second-line systemic therapy</title><p id="P20">Among our study cohort, 380 (26%) patients received both first- and second-line therapy (<xref rid="T1" ref-type="table">Table 1</xref>). This proportion varied over time starting at 25% in 2012 and ending at 23% in 2020 (<xref rid="F2" ref-type="fig">Fig. 2</xref>; <italic toggle="yes">p</italic> = 0.15). The proportion of patients receiving Chemo-only decreased from 72% in 2012 to 32% in 2020, with the nadir occurring in 2020 at 15% (<xref rid="F4" ref-type="fig">Fig. 4</xref>; <italic toggle="yes">p</italic>&lt;0.0001). Patients receiving IMO increased from 13% in 2012 to 37% in 2020 with the apex occurring in 2016 at 72% (<italic toggle="yes">p</italic>&lt;0.0001). The proportion of patients receiving Targeted agents increased from 16% in 2012 to 32% in 2020 (<italic toggle="yes">p</italic> = 0.02).</p></sec><sec id="S14"><title>First- and second-line systemic therapy by age group</title><p id="P21">Patients 35&#8211;64 years were more likely to receive first-line systemic therapy than both patients 65&#8211;74 years and patients 75&#8211;89 years (<xref rid="T2" ref-type="table">Table 2</xref>; 78% vs 70% vs 48%, respectively; <italic toggle="yes">p</italic>&lt;0.0001) and more likely to receive second-line systemic therapy (33% vs 28% vs 17%, respectively; <italic toggle="yes">p</italic>&lt;0.0001). The type of therapy received differed by age group in the first-line setting (<italic toggle="yes">p</italic> = 0.047), however did not differ in the second-line setting (<italic toggle="yes">p</italic> = 0.24).</p></sec><sec id="S15"><title>Factors associated with receipt of first-line therapy</title><p id="P22">Adjusting for all other characteristics, the likelihood of receiving first-line therapy declined with increasing age; specifically, patients 65&#8211;74 years at diagnosis were 11% less likely (PR=0.89, 95% CI: 0.82&#8211;0.96) and patients 75&#8211;89 years were 39% less likely (PR=0.61, 95% CI: 0.54&#8211;0.68) to have received first-line therapy relative to patients aged 35&#8211;64 years (<xref rid="T3" ref-type="table">Table 3</xref>). Patients who currently smoked were less likely than those who formerly smoked to have received first-line therapy (PR=0.86, 95% CI: 0.79&#8211;0.94). Conversely, the likelihood of receiving any first-line therapy was positively associated with BMI status, receipt of radiation, and year of diagnosis. Adjusting for all other characteristics, patients with a BMI 18.5&#8211;24 kg/m<sup>2</sup>, patients with a BMI 25&#8211;29 kg/m<sup>2</sup>, and patients with a BMI &gt; 30 kg/m<sup>2</sup> were all more likely than those with a BMI &lt; 18.5 kg/m<sup>2</sup> to receive first-line therapy (PR = 1.37, 95% CI: 1.05&#8211;1.78; PR = 1.44, 95% CI: 1.10&#8211;1.87; and PR = 1.48, 95% CI: 1.13&#8211;1.94, respectively). Patients who received radiation as part of first course therapy were more likely to receive first-line systemic therapy than those who did not (PR = 1.14, 95% CI: 1.06&#8211;1.23). Temporal increases were noted, with patients in 2020 38% more likely to receive first-line systemic treatment relative to those in 2012 (PR = 1.38, 95% CI: 1.13&#8211;1.68). Race and Ethnicity and Census-tract SES (measured by Yost index) were not associated with receipt of first-line therapy.</p></sec></sec><sec id="S16"><title>Discussion</title><p id="P23">Our study extends the understanding of contemporary uptake of novel systemic therapies among patients with advanced NSCLC who receive care in diverse community settings. The uptake of these novel therapies occurred quickly as demonstrated in the rapid increase of IMO regimens in our sites after FDA approval. Overall, we found 66% of individuals received any first-line systemic therapy within 180 days of diagnosis and 26% received both first- and second-line therapy within 1 year of diagnosis. Despite the uptake of these novel therapies, those at older ages continued to be less likely to receive systemic treatment compared to younger NSCLC patients. In contrast to other studies, we did not find an association between receipt of systemic therapy [<xref rid="R34" ref-type="bibr">34</xref>] and socioeconomic status [<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>] or a specific race and/or ethnicity [<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]. This is most likely due to our predominantly insured, population that was a member of, or engaged as a primary care patient with, a health system prior to diagnosis.</p><p id="P24">Our finding of 66% receiving first-line therapy falls in line with other recent studies in clinical practice settings. Voruganti and colleagues found 73.1% of patients from their select oncology practice groups to have received first-line therapy varying between 69% and 77.2% between 2011 and 2019 while our results varied between 53% and 71% between 2012 and 2020 [<xref rid="R9" ref-type="bibr">9</xref>]. These estimates were also higher than the proportion reported to have received first-line therapy in other community-based studies which estimated that 50% to 51% of patients received first-line therapy [<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R37" ref-type="bibr">37</xref>]. Our result is consistent with results found by Simeone and colleagues, where 67% of their stage IV patients received first-line systemic therapy [<xref rid="R37" ref-type="bibr">37</xref>]. Our result is less than the 79% among stage IV patients with no known genomic tumor aberrations as reported by Abernethy et al [<xref rid="R38" ref-type="bibr">38</xref>]. However, their cohort was younger with patients 18&#8211;64 years comprising 37% of their overall cohort, whereas our cohort had an age floor of 35, and those aged 35&#8211;64 years comprised 35% of our cohort. Consistent with our finding that receipt of first-line therapy is inversely related to age at diagnosis, a larger proportion of younger patients could account for the difference.</p><p id="P25">We did not find a significant increase in the use of targeted therapies as a first-line therapy over time. This could be attributed to the fact that these agents are usually only used if the tumor has certain findings on companion diagnostics. Additionally, targeted therapies have advanced the most for younger patients with adenocarcinoma[<xref rid="R16" ref-type="bibr">16</xref>] which is consistent with our finding of no secular change in the proportion of patients with adenocarcinoma between 2012 and 2020 (data not shown).</p><p id="P26">We observed 46% of our cohort receiving Chemo-only as their first-line regimen over the nine-year study period. This is consistent with previous studies that reported chemotherapy alone as the most administered first-line regimen where proportions of cohorts receiving chemotherapy alone ranged from 15% in stage IV non-squamous only patients [<xref rid="R39" ref-type="bibr">39</xref>] to 41% in stage IV Medicare patients [<xref rid="R35" ref-type="bibr">35</xref>] to 64.1% among patients mirroring clinical trials inclusion criteria [<xref rid="R37" ref-type="bibr">37</xref>] to 79.3% among stage IV patients with negative or unknown EGFR/ALK status [<xref rid="R38" ref-type="bibr">38</xref>].</p><p id="P27">We found 26% of patients received both first- and second-line therapy. This is consistent with previously published results ranging from 13% among stage IV Medicare patients [<xref rid="R35" ref-type="bibr">35</xref>] to 22.9% among stage IV patients with negative or unknown EGFR/ALK status [<xref rid="R38" ref-type="bibr">38</xref>] to 30.7% among patients in selected US oncology practices [<xref rid="R37" ref-type="bibr">37</xref>]. The use of second-line therapy had more variation across studies, indicating the complexity around decision-making in the use of second-line therapy [<xref rid="R40" ref-type="bibr">40</xref>]. The most common therapy administered in the second-line setting among patients in our cohort was Chemo-only for those 65&#8211;74 years while IMO was the most common type of therapy for those aged 35&#8211;64 years and for those 75 and older [<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R41" ref-type="bibr">41</xref>]. The spike in the receipt of IMO in 2017 for second-line therapy coincides with FDA approval of both nivolumab and pembrolizumab [<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref>].</p><sec id="S17"><title>Strengths and limitations</title><p id="P28">Our study has several strengths. In our cohort, demographic, clinical, and treatment data were derived for patients who were diagnosed with advanced lung cancer, and who receive both primary care and oncology care services in diverse community healthcare systems. This rich data source allowed us to summarize and adjust for patient level characteristics, comorbid burden, and capture all treatment data administered within the PROSPR-Lung health systems. This stands in contrast to other recent studies that employed limited data from only a select set oncology practices [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref>]. Relative to other population-based studies that reported lower levels of systemic therapy use due to the older age distribution of their Medicare only population [<xref rid="R44" ref-type="bibr">44</xref>], our study included patients ages 35 through 89 with advanced cancer. Our study design allowed for up to 12 months of follow-up for each patient and we included all patients regardless of performance status, CNS metastasis, or autoimmune disease (which excludes patients from receiving these treatments in clinical trials) [<xref rid="R45" ref-type="bibr">45</xref>]. Limitations in our study included: the lack of access to data on tumor genomic and other molecular marker testing, performance status [<xref rid="R46" ref-type="bibr">46</xref>], and specific patient characteristics that may contraindicate some treatments (e.g., nausea, vomiting, fatigue, etc.). Lastly, our cohort is predominantly insured, so our results may not be generalizable to uninsured populations diagnosed with lung cancer or those with sub-optimal access to care. Our study provides insight into the utilization of systemic therapy treatments in community practice over a period when treatment options and standards of care were rapidly evolving.</p></sec></sec><sec id="S18"><title>Conclusion</title><p id="P29">The proportion of patients in diverse community settings receiving first- and second-line systemic therapy has increased over time; particularly the proportion of patients receiving immunotherapy with or without cytotoxic chemotherapy agents. The likelihood of receiving first-line systemic therapy was inversely related to age and patients who currently smoke and was positively associated with higher BMI status, radiation as part of first course therapy, and year of diagnosis. No associations were noted for race, ethnicity, or SES. Use of emerging treatments in cancer care post-clinical trials needs to be better understood with respect to the impact of these therapies on patient outcomes, including quality of life, short- and long-term toxicities &#8211; including financial toxicities, and survival. Additional research is needed to assess the impact on the value and costs of emerging therapies in cancer care [<xref rid="R47" ref-type="bibr">47</xref>].</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS1928305-supplement-1.docx" id="d64e546" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S19"><title>Acknowledgement</title><p id="P30">Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R50CA251966 (PI: Carroll) and UM1CA221939 (MPI: Ritzwoller/Vachani). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p><sec id="S20"><title>Declaration of Competing Interest</title><p id="P31">NMC and DPR report research support from Pfizer paid to their institution, outside of the submitted work. KAR reports research support from Pfizer and AstraZeneca paid to her institution and personal fees as a scientific advisor to Merck, all outside of the submitted work. ABH reports research support from Biodesix, paid to her institution outside of the submitted work. AV reports personal fees as a scientific advisor to the Lung Cancer Initiative at Johnson &amp; Johnson and grants to his institution from MagArray, Inc., Broncus Medical, Inc., and Precyte, Inc. outside of the submitted work. AV is an advisory board member of the Lungevity Foundation (unpaid). CND reports research support from Genentech paid to her institution, outside of the submitted work. All other authors reported no conflicts of interest.</p></sec></ack><fn-group><fn id="FN1"><p id="P32">Disclaimer</p><p id="P33">Portions of this manuscript were presented in poster form at the IASLC TTLC 2022 conference, February 2022.</p></fn><fn id="FN2"><p id="P34">CRediT authorship contribution statement</p><p id="P35"><bold>Nikki M. Carroll:</bold> Conceptualization, Methodology, Software, Formal analysis, Data curation, Writing &#8211; original draft, Writing &#8211; review &amp; editing, Funding acquisition. <bold>Jennifer Eisenstein:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Andrea N. Burnett-Hartman:</bold> Conceptualization, Methodology, Writing &#8211; review &amp; editing. <bold>Robert T. Greenlee:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Stacey A. Honda:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Christine M. Neslund-Dudas:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Katharine A. Rendle:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Anil Vachani:</bold> Conceptualization, Writing &#8211; review &amp; editing. <bold>Debra P. Ritzwoller:</bold> Conceptualization, Methodology, Writing &#8211; original draft, Writing &#8211; review &amp; editing, Funding acquisition.</p></fn><fn id="FN3"><p id="P36">Supplementary materials</p><p id="P37">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1016/j.ctarc.2023.100730" ext-link-type="doi">10.1016/j.ctarc.2023.100730</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name>, <article-title>Cancer Statistics, 2021</article-title>, <source>CA Cancer J. Clin</source><volume>71</volume> (<year>2021</year>) <fpage>7</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">33433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Howlader</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Forjaz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mooradian</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Meza</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Cronin</surname><given-names>KA</given-names></name>, <etal/>, <article-title>The Effect of Advances in Lung-Cancer Treatment on Population Mortality</article-title>, <source>New Engl. J. Med</source><volume>383</volume> (<year>2020</year>) <fpage>640</fpage>&#8211;<lpage>649</lpage>.<pub-id pub-id-type="pmid">32786189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1916623</pub-id><pub-id pub-id-type="pmcid">PMC8577315</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name>, <article-title>The emerging treatment landscape of targeted therapy in non-small-cell lung cancer, Signal Transduct</article-title>. <source>Targ. Ther</source><volume>4</volume> (<year>2019</year>) <fpage>61</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-019-0099-9</pub-id><pub-id pub-id-type="pmcid">PMC6914774</pub-id><pub-id pub-id-type="pmid">31871778</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Appius</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pattipaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Feyereislova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cassidy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ganti</surname><given-names>AK</given-names></name>, <article-title>Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA</article-title>, <source>PLoS ONE</source><volume>14</volume> (<year>2019</year>), <comment>e0209709.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0209709</pub-id><pub-id pub-id-type="pmcid">PMC6319739</pub-id><pub-id pub-id-type="pmid">30608948</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Antonia</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Villegas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vicente</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>R</given-names></name>, <etal/>, <article-title>Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC</article-title>, <source>New Engl. J. Med</source><volume>379</volume> (<year>2018</year>) <fpage>2342</fpage>&#8211;<lpage>2350</lpage>.<pub-id pub-id-type="pmid">30280658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1809697</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Camidge</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name>, <etal/>, <article-title>Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer</article-title>, <source>New Engl. J. Med</source><volume>379</volume> (<year>2018</year>) <fpage>2027</fpage>&#8211;<lpage>2039</lpage>.<pub-id pub-id-type="pmid">30280657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1810171</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gray</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Villegas</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Vicente</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>R</given-names></name>, <etal/>, <article-title>Three-year overall survival update from the PACIFIC trial</article-title>, <source>J. Clin. Oncol</source><volume>37</volume> (<year>2019</year>) <fpage>8526</fpage>.</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tan</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Takano</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Newell</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Iyer</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>WT</given-names></name>, <etal/>, <article-title>Novel therapeutic targets on the horizon for lung cancer</article-title>, <source>Lancet Oncol</source>. <volume>17</volume> (<year>2016</year>) <fpage>e347</fpage>&#8211;<lpage>ee62</lpage>.<pub-id pub-id-type="pmid">27511159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(16)30123-1</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Voruganti</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Soulos</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Mamtani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Presley</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Gross</surname><given-names>CP</given-names></name>, <article-title>Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy</article-title>, <source>JAMA Oncol</source>. (<year>2023</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.6901</pub-id><pub-id pub-id-type="pmcid">PMC9880865</pub-id><pub-id pub-id-type="pmid">36701150</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Minguet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Bramlage</surname><given-names>P</given-names></name>, <article-title>Targeted therapies for treatment of non-small cell lung cancer&#8211;Recent advances and future perspectives</article-title>, <source>Int. J. Cancer</source><volume>138</volume> (<year>2016</year>) <fpage>2549</fpage>&#8211;<lpage>2561</lpage>.<pub-id pub-id-type="pmid">26537995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29915</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reck</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cs&#337;szi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>F&#252;l&#246;p</surname><given-names>A</given-names></name>, <etal/>, <article-title>Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer</article-title>, <source>New Engl. J. Med</source><volume>375</volume> (<year>2016</year>) <fpage>1823</fpage>&#8211;<lpage>1833</lpage>.<pub-id pub-id-type="pmid">27718847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1606774</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brahmer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Reckamp</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Baas</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Crin&#242;</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Eberhardt</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Poddubskaya</surname><given-names>E</given-names></name>, <etal/>, <article-title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer</article-title>, <source>New Engl. J. Med</source><volume>373</volume> (<year>2015</year>) <fpage>123</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="pmid">26028407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1504627</pub-id><pub-id pub-id-type="pmcid">PMC4681400</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rittmeyer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Barlesi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Waterkamp</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ciardiello</surname><given-names>F</given-names></name>, <name name-style="western"><surname>von Pawel</surname><given-names>J</given-names></name>, <etal/>, <article-title>Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial</article-title>, <source>Lancet</source><volume>389</volume> (<year>2017</year>) <fpage>255</fpage>&#8211;<lpage>265</lpage>.<pub-id pub-id-type="pmid">27979383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32517-X</pub-id><pub-id pub-id-type="pmcid">PMC6886121</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Borghaei</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Paz-Ares</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Spigel</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Steins</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ready</surname><given-names>NE</given-names></name>, <etal/>, <article-title>Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer</article-title>, <source>New Engl. J. Med</source><volume>373</volume> (<year>2015</year>) <fpage>1627</fpage>&#8211;<lpage>1639</lpage>.<pub-id pub-id-type="pmid">26412456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1507643</pub-id><pub-id pub-id-type="pmcid">PMC5705936</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hellmann</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Ciuleanu</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Pluzanski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Otterson</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Audigier-Valette</surname><given-names>C</given-names></name>, <etal/>, <article-title>Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden</article-title>, <source>New Engl. J. Med</source><volume>378</volume> (<year>2018</year>) <fpage>2093</fpage>&#8211;<lpage>2104</lpage>.<pub-id pub-id-type="pmid">29658845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1801946</pub-id><pub-id pub-id-type="pmcid">PMC7193684</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hirsch</surname><given-names>FR</given-names></name>, <name name-style="western"><surname>Scagliotti</surname><given-names>GV</given-names></name>, <name name-style="western"><surname>Mulshine</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Curran</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YL</given-names><suffix>Jr.</suffix></name>, <etal/>, <article-title>Lung cancer: current therapies and new targeted treatments</article-title>, <source>Lancet</source><volume>389</volume> (<year>2017</year>) <fpage>299</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">27574741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)30958-8</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="book"><collab>NCC</collab>. <part-title>NCCN Network, Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer</part-title>. <comment>Version 4.2021 ed.</comment><source>Cold Spring Harbor</source>, <publisher-name>Harborside Press</publisher-name>, <publisher-loc>New York</publisher-loc>, <year>2021</year>. <comment>LLC.</comment></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arbour</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Riely</surname><given-names>GJ</given-names></name>, <article-title>Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review</article-title>, <source>JAMA</source><volume>322</volume> (<year>2019</year>) <fpage>764</fpage>&#8211;<lpage>774</lpage>.<pub-id pub-id-type="pmid">31454018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.11058</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sherman</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Dal Pan</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Gross</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>NL</given-names></name>, <etal/>, <article-title>Real-World Evidence - What Is It and What Can It Tell Us?</article-title><source>New Engl. J. Med</source><volume>375</volume> (<year>2016</year>) <fpage>2293</fpage>&#8211;<lpage>2297</lpage>.<pub-id pub-id-type="pmid">27959688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMsb1609216</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rendle</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Burnett-Hartman</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Neslund-Dudas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Greenlee</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Elston Lafata</surname><given-names>J</given-names></name>, <etal/>, <article-title>Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium</article-title>, <source>Cancer Prev. Res. (Phila)</source><volume>13</volume> (<year>2020</year>) <fpage>129</fpage>&#8211;<lpage>136</lpage>.<pub-id pub-id-type="pmid">31871221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-19-0378</pub-id><pub-id pub-id-type="pmcid">PMC7010351</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Burnett-Hartman</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mitra</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Neslund-Dudas</surname><given-names>C</given-names></name>, <etal/>, <article-title>Community-based Lung Cancer Screening Results in Relation to Patient and Radiologist Characteristics: the PROSPR Consortium</article-title>. <source>Annals of the, American Thoracic Society</source>, <year>2021</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.202011-1413OC</pub-id><pub-id pub-id-type="pmcid">PMC8937226</pub-id><pub-id pub-id-type="pmid">34543590</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ritzwoller</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Meza</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Blum-Barnett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Burnett-Hartman</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Greenlee</surname><given-names>RT</given-names></name>, <etal/>, <article-title>Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems</article-title>, <source>JAMA Netw. Open</source><volume>4</volume> (<year>2021</year>), <comment>e2128176.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.28176</pub-id><pub-id pub-id-type="pmcid">PMC8511972</pub-id><pub-id pub-id-type="pmid">34636916</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rendle</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Neslund-Dudas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Greenlee</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Burnett-Hartman</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>SA</given-names></name>, <etal/>, <article-title>Community-based lung cancer screening adherence to Lung-RADS recommendations</article-title>, <source>J. Clin. Oncol</source><volume>39</volume> (<year>2021</year>) <fpage>10540</fpage>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="other"><collab>North American Association of Central Cencer Registries</collab>, <source>NAACCR Strategic Management Plan</source>, <year>2020</year>.</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Charlson</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Charlson</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Marinopoulos</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Briggs</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Hollenberg</surname><given-names>JP</given-names></name>, <article-title>The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients</article-title>, <source>J. Clin. Epidemiol</source><volume>61</volume> (<year>2008</year>) <fpage>1234</fpage>&#8211;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">18619805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2008.01.006</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Deyo</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Cherkin</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Ciol</surname><given-names>MA</given-names></name>, <article-title>Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases</article-title>, <source>J. Clin. Epidemiol</source><volume>45</volume> (<year>1992</year>) <fpage>613</fpage>&#8211;<lpage>619</lpage>.<pub-id pub-id-type="pmid">1607900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0895-4356(92)90133-8</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tatalovich</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Cronin</surname><given-names>KA</given-names></name>, <article-title>Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data</article-title>, <source>Cancer Causes Control</source><volume>25</volume> (<year>2014</year>) <fpage>81</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">24178398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-013-0310-1</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ritzwoller</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Delate</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hornbrook</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Kushi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Aiello Bowles</surname><given-names>EJ</given-names></name>, <etal/>, <article-title>Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network</article-title>, <source>Lung Cancer</source><volume>78</volume> (<year>2012</year>) <fpage>245</fpage>&#8211;<lpage>252</lpage>.<pub-id pub-id-type="pmid">23022316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2012.09.008</pub-id><pub-id pub-id-type="pmcid">PMC3490021</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Delate</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Menter</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hornbrook</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Kushi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Aiello Bowles</surname><given-names>EJ</given-names></name>, <etal/>, <article-title>Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer</article-title>, <source>J. Oncol. Pract</source><volume>11</volume> (<year>2015</year>) <fpage>356</fpage>&#8211;<lpage>362</lpage>.<pub-id pub-id-type="pmid">26060223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JOP.2014.002980</pub-id><pub-id pub-id-type="pmcid">PMC4575400</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Delate</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bowles</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Pardee</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wellman</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Habel</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Yood</surname><given-names>MU</given-names></name>, <etal/>, <article-title>Validity of eight integrated healthcare delivery organizations&#8217; administrative clinical data to capture breast cancer chemotherapy exposure</article-title>, <source>Cancer Epidemiol. Biomarkers Prev</source><volume>21</volume> (<year>2012</year>) <fpage>673</fpage>&#8211;<lpage>680</lpage>.<pub-id pub-id-type="pmid">22337532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-11-1075</pub-id><pub-id pub-id-type="pmcid">PMC3319397</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ritzwoller</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Delate</surname><given-names>T</given-names></name>, <name name-style="western"><surname>O&#8217;Keeffe-Rossetti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fishman</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Loggers</surname><given-names>ET</given-names></name>, <etal/>, <article-title>Validation of electronic data on chemotherapy and hormone therapy use in HMOs</article-title>, <source>Med. Care</source><volume>51</volume> (<year>2013</year>) <fpage>e67</fpage>&#8211;<lpage>e73</lpage>.<pub-id pub-id-type="pmid">22531648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0b013e31824def85</pub-id><pub-id pub-id-type="pmcid">PMC3406224</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Burniece</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Holzman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>McQuillan</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Plata</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ritzwoller</surname><given-names>DP</given-names></name>, <article-title>Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data</article-title>, <source>JCO Clin. Cancer Inform</source><volume>1</volume> (<year>2017</year>) <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/CCI.17.00002</pub-id><pub-id pub-id-type="pmcid">PMC7006900</pub-id><pub-id pub-id-type="pmid">30657379</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Azur</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Frangakis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leaf</surname><given-names>PJ</given-names></name>, <article-title>Multiple imputation by chained equations: what is it and how does it work?</article-title><source>Int. J. Methods Psychiatr. Res</source><volume>20</volume> (<year>2011</year>) <fpage>40</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">21499542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mpr.329</pub-id><pub-id pub-id-type="pmcid">PMC3074241</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maguire</surname><given-names>FB</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Parikh-Patel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cress</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Keegan</surname><given-names>THM</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>CS</given-names></name>, <etal/>, <article-title>First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting</article-title>, <source>JNCI Cancer Spectrum</source><volume>3</volume> (<year>2019</year>) <fpage>pkz020</fpage>.<pub-id pub-id-type="pmid">32328551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkz020</pub-id><pub-id pub-id-type="pmcid">PMC7050031</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kehl</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Hassett</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Schrag</surname><given-names>D</given-names></name>. <article-title>Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era</article-title>, <source>Cancer Med</source>. <volume>9</volume> (<year>2020</year>) <fpage>2019</fpage>&#8211;<lpage>2029</lpage>.<pub-id pub-id-type="pmid">31989786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2854</pub-id><pub-id pub-id-type="pmcid">PMC7064091</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Davis</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Goyal</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Able</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kaye</surname><given-names>JA</given-names></name>, <article-title>Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer</article-title>, <source>Lung Cancer</source><volume>87</volume> (<year>2015</year>) <fpage>176</fpage>&#8211;<lpage>185</lpage>.<pub-id pub-id-type="pmid">25532680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2014.11.002</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Simeone</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Nordstrom</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>AB</given-names></name>, <article-title>Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting</article-title>, <source>Future Oncol</source>. <volume>15</volume> (<year>2019</year>) <fpage>3491</fpage>&#8211;<lpage>3502</lpage>.<pub-id pub-id-type="pmid">31497994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2019-0348</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abernethy</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Arunachalam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>T</given-names></name>, <name name-style="western"><surname>McKay</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sorg</surname><given-names>R</given-names></name>, <etal/>, <article-title>Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting</article-title>, <source>PLoS ONE</source><volume>12</volume> (<year>2017</year>), <fpage>e0178420</fpage>.<pub-id pub-id-type="pmid">28644837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0178420</pub-id><pub-id pub-id-type="pmcid">PMC5482433</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Seung</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Hurry</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walton</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>WK</given-names></name>, <article-title>Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada</article-title>, <source>Curr. Oncol</source><volume>27</volume> (<year>2020</year>) <fpage>e361</fpage>&#8211;<lpage>e3e7</lpage>.<pub-id pub-id-type="pmid">32905294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/co.27.6049</pub-id><pub-id pub-id-type="pmcid">PMC7467785</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fr&#252;h</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Panje</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Reck</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Blackhall</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Califano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cappuzzo</surname><given-names>F</given-names></name>, <etal/>, <article-title>Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts</article-title>, <source>Lung Cancer</source><volume>146</volume> (<year>2020</year>) <fpage>6</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">32485661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2020.03.024</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nadler</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Espirito</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Pavilack</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vergara-Silva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fernandes</surname><given-names>A</given-names></name>, <article-title>Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting</article-title>, <source>Clin. Lung Cancer</source><volume>19</volume> (<year>2018</year>) <fpage>360</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">29576407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cllc.2018.02.002</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gandara</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Riess</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mack</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Lara</surname><given-names>PN</given-names><suffix>Jr.</suffix></name>, <article-title>Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer</article-title>, <source>Clin. Lung Cancer</source><volume>18</volume> (<year>2017</year>) <fpage>1</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">28082049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cllc.2016.12.011</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khozin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Abernethy</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Nussbaum</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Zhi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Tucker</surname><given-names>M</given-names></name>, <etal/>, <article-title>Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval</article-title>, <source>Oncologist</source><volume>23</volume> (<year>2018</year>) <fpage>328</fpage>&#8211;<lpage>336</lpage>.<pub-id pub-id-type="pmid">29317551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2017-0353</pub-id><pub-id pub-id-type="pmcid">PMC5905694</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Warren</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Klabunde</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Schrag</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bach</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Riley</surname><given-names>GF</given-names></name>, <article-title>Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population</article-title>, <source>Med. Care</source><volume>40</volume> (<year>2002</year>) <comment>Iv-3&#8211;18.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.MLR.0000020942.47004.03</pub-id><pub-id pub-id-type="pmid">12187163</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rashdan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gerber</surname><given-names>DE</given-names></name>, <article-title>Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice</article-title>, <source>Transl. Lung Cancer Res</source><volume>8</volume> (<year>2019</year>) <fpage>202</fpage>&#8211;<lpage>207</lpage>.<pub-id pub-id-type="pmid">31367533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2018.09.15</pub-id><pub-id pub-id-type="pmcid">PMC6626864</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Castro</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kudaba</surname><given-names>I</given-names><suffix>Jr.</suffix></name>, <name name-style="western"><surname>Wu</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Lopes</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kowalski</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Turna</surname><given-names>HZ</given-names></name>, <etal/>, <article-title>Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score &#8805; 1% in the KEYNOTE-042 Study</article-title>, <source>J. Clin. Oncol</source> (<year>2022</year>), <comment>Jco2102885.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.02885</pub-id><pub-id pub-id-type="pmcid">PMC10082298</pub-id><pub-id pub-id-type="pmid">36306479</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Giuliani</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bonetti</surname><given-names>A</given-names></name>, <article-title>Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors</article-title>, <source>Anticancer Res</source>. <volume>39</volume> (<year>2019</year>) <fpage>3961</fpage>&#8211;<lpage>3965</lpage>.<pub-id pub-id-type="pmid">31262928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.13550</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p id="P38">Selection of patients with advanced NSCLC for analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1928305-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p id="P39">Proportion of patients with advanced NSCLC receiving first- and second-line systemic therapy, 2012&#8211;2020.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1928305-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p id="P40">Type of first-line systemic therapy received among patients diagnosed with advanced NSCLC, 2012&#8211;2020.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1928305-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p id="P41">Type of second-line systemic therapy received by patients diagnosed with advanced NSCLC, 2012&#8211;2020.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1928305-f0004.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p id="P42">Demographic and clinical characteristics of patients diagnosed with advanced NSCLC.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">Patients diagnosed with Stage IV NSCLC</th><th colspan="2" align="left" valign="top" rowspan="1">Patients Receiving First-Line Systemic Therapy within 180 Days of Diagnosis</th><th colspan="2" align="left" valign="top" rowspan="1">Patients Receiving Second-Line Systemic Therapy within 1 Year of Diagnosis</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">% of patients diagnosed with NSCLC</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">% of patients diagnosed with NSCLC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TOTAL</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">1442</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">949</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">380</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Morphology</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Squamous</td><td align="left" valign="top" rowspan="1" colspan="1">1204</td><td align="left" valign="top" rowspan="1" colspan="1">83%</td><td align="left" valign="top" rowspan="1" colspan="1">787</td><td align="left" valign="top" rowspan="1" colspan="1">65%</td><td align="left" valign="top" rowspan="1" colspan="1">305</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous</td><td align="left" valign="top" rowspan="1" colspan="1">238</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td><td align="left" valign="top" rowspan="1" colspan="1">162</td><td align="left" valign="top" rowspan="1" colspan="1">68%</td><td align="left" valign="top" rowspan="1" colspan="1">75</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">719</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">475</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">191</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">723</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">474</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">189</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Race/Ethnicity</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="left" valign="top" rowspan="1" colspan="1">142</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">99</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">33</td><td align="left" valign="top" rowspan="1" colspan="1">23%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">171</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">101</td><td align="left" valign="top" rowspan="1" colspan="1">59%</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Native Hawaiian/Pacific Islander</td><td align="left" valign="top" rowspan="1" colspan="1">77</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">54</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="left" valign="top" rowspan="1" colspan="1">59</td><td align="left" valign="top" rowspan="1" colspan="1">4%</td><td align="left" valign="top" rowspan="1" colspan="1">33</td><td align="left" valign="top" rowspan="1" colspan="1">56%</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other/Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">78</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">21%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Hispanic White</td><td align="left" valign="top" rowspan="1" colspan="1">915</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">615</td><td align="left" valign="top" rowspan="1" colspan="1">67%</td><td align="left" valign="top" rowspan="1" colspan="1">252</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age at diagnosis (years)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">35 &#8211; 64</td><td align="left" valign="top" rowspan="1" colspan="1">505</td><td align="left" valign="top" rowspan="1" colspan="1">35%</td><td align="left" valign="top" rowspan="1" colspan="1">393</td><td align="left" valign="top" rowspan="1" colspan="1">78%</td><td align="left" valign="top" rowspan="1" colspan="1">165</td><td align="left" valign="top" rowspan="1" colspan="1">33%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">65 &#8211; 74</td><td align="left" valign="top" rowspan="1" colspan="1">486</td><td align="left" valign="top" rowspan="1" colspan="1">34%</td><td align="left" valign="top" rowspan="1" colspan="1">342</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">138</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">75 &#8211; 89</td><td align="left" valign="top" rowspan="1" colspan="1">451</td><td align="left" valign="top" rowspan="1" colspan="1">31%</td><td align="left" valign="top" rowspan="1" colspan="1">214</td><td align="left" valign="top" rowspan="1" colspan="1">47%</td><td align="left" valign="top" rowspan="1" colspan="1">78</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Smoking status at diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Current</td><td align="left" valign="top" rowspan="1" colspan="1">426</td><td align="left" valign="top" rowspan="1" colspan="1">30%</td><td align="left" valign="top" rowspan="1" colspan="1">266</td><td align="left" valign="top" rowspan="1" colspan="1">62%</td><td align="left" valign="top" rowspan="1" colspan="1">102</td><td align="left" valign="top" rowspan="1" colspan="1">24%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="left" valign="top" rowspan="1" colspan="1">247</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td><td align="left" valign="top" rowspan="1" colspan="1">185</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">80</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Former</td><td align="left" valign="top" rowspan="1" colspan="1">684</td><td align="left" valign="top" rowspan="1" colspan="1">47%</td><td align="left" valign="top" rowspan="1" colspan="1">447</td><td align="left" valign="top" rowspan="1" colspan="1">65%</td><td align="left" valign="top" rowspan="1" colspan="1">181</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown/Missing</td><td align="left" valign="top" rowspan="1" colspan="1">85</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">51</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Health system</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare System 1</td><td align="left" valign="top" rowspan="1" colspan="1">375</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td><td align="left" valign="top" rowspan="1" colspan="1">236</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">81</td><td align="left" valign="top" rowspan="1" colspan="1">22%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare System 2</td><td align="left" valign="top" rowspan="1" colspan="1">591</td><td align="left" valign="top" rowspan="1" colspan="1">41%</td><td align="left" valign="top" rowspan="1" colspan="1">370</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">151</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare System 3</td><td align="left" valign="top" rowspan="1" colspan="1">282</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td><td align="left" valign="top" rowspan="1" colspan="1">196</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">81</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare System 4</td><td align="left" valign="top" rowspan="1" colspan="1">194</td><td align="left" valign="top" rowspan="1" colspan="1">13%</td><td align="left" valign="top" rowspan="1" colspan="1">147</td><td align="left" valign="top" rowspan="1" colspan="1">76%</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">35%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Charlson Co-morbidity Index (1 year prior to diagnosis)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">253</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">185</td><td align="left" valign="top" rowspan="1" colspan="1">73%</td><td align="left" valign="top" rowspan="1" colspan="1">88</td><td align="left" valign="top" rowspan="1" colspan="1">35%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1&#8211;2</td><td align="left" valign="top" rowspan="1" colspan="1">363</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">245</td><td align="left" valign="top" rowspan="1" colspan="1">67%</td><td align="left" valign="top" rowspan="1" colspan="1">95</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3+</td><td align="left" valign="top" rowspan="1" colspan="1">826</td><td align="left" valign="top" rowspan="1" colspan="1">57%</td><td align="left" valign="top" rowspan="1" colspan="1">519</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">197</td><td align="left" valign="top" rowspan="1" colspan="1">24%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BMI status at diagnosis, kg/m</bold>
<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&lt; 18.5</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">15%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18.5 &#8211; 24</td><td align="left" valign="top" rowspan="1" colspan="1">580</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">364</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">140</td><td align="left" valign="top" rowspan="1" colspan="1">24%</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">25 &#8211; 29</td><td align="left" valign="top" rowspan="1" colspan="1">445</td><td align="left" valign="top" rowspan="1" colspan="1">31%</td><td align="left" valign="top" rowspan="1" colspan="1">304</td><td align="left" valign="top" rowspan="1" colspan="1">68%</td><td align="left" valign="top" rowspan="1" colspan="1">123</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30 +</td><td align="left" valign="top" rowspan="1" colspan="1">314</td><td align="left" valign="top" rowspan="1" colspan="1">22%</td><td align="left" valign="top" rowspan="1" colspan="1">229</td><td align="left" valign="top" rowspan="1" colspan="1">73%</td><td align="left" valign="top" rowspan="1" colspan="1">96</td><td align="left" valign="top" rowspan="1" colspan="1">31%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">2%</td><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">31%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Yost state quintile (census data)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 5 (highest)</td><td align="left" valign="top" rowspan="1" colspan="1">326</td><td align="left" valign="top" rowspan="1" colspan="1">23%</td><td align="left" valign="top" rowspan="1" colspan="1">198</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">85</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 4</td><td align="left" valign="top" rowspan="1" colspan="1">276</td><td align="left" valign="top" rowspan="1" colspan="1">19%</td><td align="left" valign="top" rowspan="1" colspan="1">176</td><td align="left" valign="top" rowspan="1" colspan="1">64%</td><td align="left" valign="top" rowspan="1" colspan="1">75</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 3</td><td align="left" valign="top" rowspan="1" colspan="1">282</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td><td align="left" valign="top" rowspan="1" colspan="1">193</td><td align="left" valign="top" rowspan="1" colspan="1">68%</td><td align="left" valign="top" rowspan="1" colspan="1">78</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 2</td><td align="left" valign="top" rowspan="1" colspan="1">257</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">180</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 1 (lowest)</td><td align="left" valign="top" rowspan="1" colspan="1">258</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">171</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">61</td><td align="left" valign="top" rowspan="1" colspan="1">24%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">72%</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">37%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of surgery as part of first course therapy (tumor registry)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">1406</td><td align="left" valign="top" rowspan="1" colspan="1">98%</td><td align="left" valign="top" rowspan="1" colspan="1">926</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">373</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">2%</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">64%</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">19%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of radiation as part of first course therapy (tumor registry)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">825</td><td align="left" valign="top" rowspan="1" colspan="1">46%</td><td align="left" valign="top" rowspan="1" colspan="1">502</td><td align="left" valign="top" rowspan="1" colspan="1">55%</td><td align="left" valign="top" rowspan="1" colspan="1">202</td><td align="left" valign="top" rowspan="1" colspan="1">24%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">617</td><td align="left" valign="top" rowspan="1" colspan="1">43%</td><td align="left" valign="top" rowspan="1" colspan="1">447</td><td align="left" valign="top" rowspan="1" colspan="1">72%</td><td align="left" valign="top" rowspan="1" colspan="1">178</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of lung cancer screening (prior to diagnosis)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">1399</td><td align="left" valign="top" rowspan="1" colspan="1">97%</td><td align="left" valign="top" rowspan="1" colspan="1">922</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">367</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">30%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Year of diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2012</td><td align="left" valign="top" rowspan="1" colspan="1">129</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">53%</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">172</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">105</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2014</td><td align="left" valign="top" rowspan="1" colspan="1">171</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">113</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">48</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2015</td><td align="left" valign="top" rowspan="1" colspan="1">205</td><td align="left" valign="top" rowspan="1" colspan="1">14%</td><td align="left" valign="top" rowspan="1" colspan="1">125</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">51</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2016</td><td align="left" valign="top" rowspan="1" colspan="1">180</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">129</td><td align="left" valign="top" rowspan="1" colspan="1">72%</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">36%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2017</td><td align="left" valign="top" rowspan="1" colspan="1">206</td><td align="left" valign="top" rowspan="1" colspan="1">14%</td><td align="left" valign="top" rowspan="1" colspan="1">142</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">59</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2018</td><td align="left" valign="top" rowspan="1" colspan="1">172</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">122</td><td align="left" valign="top" rowspan="1" colspan="1">71%</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">23%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2019</td><td align="left" valign="top" rowspan="1" colspan="1">124</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">85</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">16%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2020</td><td align="left" valign="top" rowspan="1" colspan="1">83</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">59</td><td align="left" valign="top" rowspan="1" colspan="1">71%</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">23%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2</label><caption><p id="P43">First- and second-line systemic therapy received by patients with advanced NSCLC stratified by age</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">35 &#8211; 64 Years</th><th colspan="2" align="left" valign="top" rowspan="1">65 &#8211; 74 Years</th><th colspan="2" align="left" valign="top" rowspan="1">75 &#8211; 89 Years</th><th colspan="2" align="left" valign="top" rowspan="1">Total</th><th align="left" valign="top" rowspan="1" colspan="1">p-value<xref rid="TFN1" ref-type="table-fn">*</xref></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total patients diagnosed with lung cancer</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">505</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">486</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">451</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1442</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total patients receiving first-line systemic therapy</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">393</td><td align="left" valign="top" rowspan="1" colspan="1">78%</td><td align="left" valign="top" rowspan="1" colspan="1">342</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">214</td><td align="left" valign="top" rowspan="1" colspan="1">48%</td><td align="left" valign="top" rowspan="1" colspan="1">949</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&lt; 0.0001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Type of first line systemic therapy</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.047</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemo-Only</td><td align="left" valign="top" rowspan="1" colspan="1">169</td><td align="left" valign="top" rowspan="1" colspan="1">43%</td><td align="left" valign="top" rowspan="1" colspan="1">164</td><td align="left" valign="top" rowspan="1" colspan="1">48%</td><td align="left" valign="top" rowspan="1" colspan="1">107</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">440</td><td align="left" valign="top" rowspan="1" colspan="1">46%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IMO</td><td align="left" valign="top" rowspan="1" colspan="1">148</td><td align="left" valign="top" rowspan="1" colspan="1">38%</td><td align="left" valign="top" rowspan="1" colspan="1">136</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td><td align="left" valign="top" rowspan="1" colspan="1">353</td><td align="left" valign="top" rowspan="1" colspan="1">37%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Targeted</td><td align="left" valign="top" rowspan="1" colspan="1">76</td><td align="left" valign="top" rowspan="1" colspan="1">19%</td><td align="left" valign="top" rowspan="1" colspan="1">42</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">156</td><td align="left" valign="top" rowspan="1" colspan="1">16%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total patients receiving first- and second-line systemic therapy</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">164</td><td align="left" valign="top" rowspan="1" colspan="1">33%</td><td align="left" valign="top" rowspan="1" colspan="1">138</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td><td align="left" valign="top" rowspan="1" colspan="1">78</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td><td align="left" valign="top" rowspan="1" colspan="1">380</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&lt; 0.0001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Type of second line systemic therapy</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemo-Only</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">66</td><td align="left" valign="top" rowspan="1" colspan="1">48%</td><td align="left" valign="top" rowspan="1" colspan="1">26</td><td align="left" valign="top" rowspan="1" colspan="1">33%</td><td align="left" valign="top" rowspan="1" colspan="1">157</td><td align="left" valign="top" rowspan="1" colspan="1">41%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IMO</td><td align="left" valign="top" rowspan="1" colspan="1">73</td><td align="left" valign="top" rowspan="1" colspan="1">45%</td><td align="left" valign="top" rowspan="1" colspan="1">58</td><td align="left" valign="top" rowspan="1" colspan="1">42%</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">55%</td><td align="left" valign="top" rowspan="1" colspan="1">174</td><td align="left" valign="top" rowspan="1" colspan="1">46%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Targeted</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">14%</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P44">Compared using the chi-square test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="landscape"><label>Table 3</label><caption><p id="P45">Demographic and clinical factors associated with receipt of first-line systemic therapy within 180 days of advanced NSCLC diagnosis<sup><xref rid="TFN3" ref-type="table-fn">a</xref></sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Percent of Stage IV NSCLC patients with this characteristic</th><th align="left" valign="top" rowspan="1" colspan="1">Percent of Stage IV NSCLC patients who received first-line systemic therapy</th><th align="left" valign="top" rowspan="1" colspan="1">Unadjusted PRs and 95% CI of patient characteristic on receipt of first-line systemic therapy</th><th align="left" valign="top" rowspan="1" colspan="1">Adjusted PRs and 95% CIs of patient characteristic on receipt of first-line systemic therapy</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">PR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">PR (95% CI)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Histology</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Squamous</td><td align="left" valign="top" rowspan="1" colspan="1">84%</td><td align="left" valign="top" rowspan="1" colspan="1">65%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td><td align="left" valign="top" rowspan="1" colspan="1">68%</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (0.95 &#8211; 1.15)</td><td align="left" valign="top" rowspan="1" colspan="1">1.08 (0.98 &#8211; 1.18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">1.01 (0.94 &#8211; 1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">1.01 (0.94 &#8211; 1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Race/Ethnicity</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non- Hispanic White</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">67%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (0.92 &#8211; 1.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99 (0.86 &#8211; 1.15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">59%</td><td align="left" valign="top" rowspan="1" colspan="1">0.88 (0.77 &#8211; 1.003)</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.80 &#8211; 1.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Native Hawaiian/Pacific Islander</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (0.90 &#8211; 1.22)</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.82 &#8211; 1.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="left" valign="top" rowspan="1" colspan="1">4%</td><td align="left" valign="top" rowspan="1" colspan="1">56%</td><td align="left" valign="top" rowspan="1" colspan="1">0.83 (0.66 &#8211; 1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">0.87 (0.70 &#8211; 1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other/Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.74 &#8211; 1.08)</td><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.76 &#8211; 1.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age at diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">35 &#8211; 64</td><td align="left" valign="top" rowspan="1" colspan="1">35%</td><td align="left" valign="top" rowspan="1" colspan="1">78%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">65 &#8211; 74</td><td align="left" valign="top" rowspan="1" colspan="1">34%</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.84 &#8211; 0.97)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.89 (0.82 &#8211; 0.96)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">75 &#8211; 89</td><td align="left" valign="top" rowspan="1" colspan="1">31%</td><td align="left" valign="top" rowspan="1" colspan="1">47%</td><td align="left" valign="top" rowspan="1" colspan="1">0.61 (0.55 &#8211; 0.68)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.61 (0.54 &#8211; 0.68)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Smoking status at diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Former</td><td align="left" valign="top" rowspan="1" colspan="1">47%</td><td align="left" valign="top" rowspan="1" colspan="1">65%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Current</td><td align="left" valign="top" rowspan="1" colspan="1">30%</td><td align="left" valign="top" rowspan="1" colspan="1">62%</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.87 &#8211; 1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.86 (0.79 &#8211; 0.94)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="left" valign="top" rowspan="1" colspan="1">17%</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">1.15 (1.05 &#8211; 1.56)</td><td align="left" valign="top" rowspan="1" colspan="1">1.08 (0.99 &#8211; 1.18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.77 &#8211; 1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.78 &#8211; 1.12)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Charlson Co-morbidity Index</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">73%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1&#8211;2</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">67%</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.83 &#8211; 1.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.89 &#8211; 1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3+</td><td align="left" valign="top" rowspan="1" colspan="1">57%</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">0.86 (0.78 &#8211; 0.94)</td><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.85 &#8211; 1.01)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BMI status at diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&lt; 18.5</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">42%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18.5 &#8211; 24</td><td align="left" valign="top" rowspan="1" colspan="1">41%</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">1.51 (1.13 &#8211; 2.01)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.37 (1.05 &#8211; 1.78)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">25 &#8211; 29</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td><td align="left" valign="top" rowspan="1" colspan="1">68%</td><td align="left" valign="top" rowspan="1" colspan="1">1.64 (1.23 &#8211; 2.19)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.44 (1.10 &#8211; 1.87)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30 +</td><td align="left" valign="top" rowspan="1" colspan="1">22%</td><td align="left" valign="top" rowspan="1" colspan="1">73%</td><td align="left" valign="top" rowspan="1" colspan="1">1.75 (1.31 &#8211; 2.34)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.48 (1.13 &#8211; 1.94)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Yost State Quintile (Census based)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 5 (Highest)</td><td align="left" valign="top" rowspan="1" colspan="1">23%</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 4</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td><td align="left" valign="top" rowspan="1" colspan="1">64%</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (0.94 &#8211; 1.19)</td><td align="left" valign="top" rowspan="1" colspan="1">1.03 (0.92 &#8211; 1.15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 3</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">1.03 (0.92 &#8211; 1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.89 &#8211; 1.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 2</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.85 &#8211; 1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.82 &#8211; 1.05)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quintile 1 (Lowest)</td><td align="left" valign="top" rowspan="1" colspan="1">18%</td><td align="left" valign="top" rowspan="1" colspan="1">67%</td><td align="left" valign="top" rowspan="1" colspan="1">0.91 (0.81 &#8211; 1.04)</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.83 &#8211; 1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of surgery as part of first course therapy (tumor registry)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">98%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">64%</td><td align="left" valign="top" rowspan="1" colspan="1">0.97 (0.76 &#8211; 1.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.77 &#8211; 1.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of radiation as part of first course therapy (tumor registry)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">57%</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">43%</td><td align="left" valign="top" rowspan="1" colspan="1">72%</td><td align="left" valign="top" rowspan="1" colspan="1">1.19 (1.11 &#8211; 1.28)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.14 (1.06 &#8211; 1.23)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Receipt of lung cancer screening (prior to diagnosis)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">97%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">63%</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.76 &#8211; 1.20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.78 &#8211; 1.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Year of Diagnosis</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2012</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">53%</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td><td align="left" valign="top" rowspan="1" colspan="1">[Ref]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">1.14 (0.93 &#8211; 1.40)</td><td align="left" valign="top" rowspan="1" colspan="1">1.18 (0.97 &#8211; 1.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2014</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">1.24 (1.02 &#8211; 1.50)</td><td align="left" valign="top" rowspan="1" colspan="1">1.18 (0.98 &#8211; 1.42)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2015</td><td align="left" valign="top" rowspan="1" colspan="1">14%</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">1.14 (0.94 &#8211; 1.39)</td><td align="left" valign="top" rowspan="1" colspan="1">1.12 (0.93 &#8211; 1.35)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2016</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">72%</td><td align="left" valign="top" rowspan="1" colspan="1">1.34 (1.11 &#8211; 1.61)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.26 (1.05 &#8211; 1.51)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2017</td><td align="left" valign="top" rowspan="1" colspan="1">14%</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">1.29 (1.07 &#8211; 1.55)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.27 (1.07 &#8211; 1.52)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2018</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">71%</td><td align="left" valign="top" rowspan="1" colspan="1">1.33 (1.10 &#8211; 1.60)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.28 (1.07 &#8211; 1.53)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2019</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">69%</td><td align="left" valign="top" rowspan="1" colspan="1">1.28 (1.05 &#8211; 1.57)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.33 (1.09 &#8211; 1.61)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2020</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">71%</td><td align="left" valign="top" rowspan="1" colspan="1">1.33 (1.08 &#8211; 1.64)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.38 (1.13 &#8211; 1.68)</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p id="P46">Abbreviations: Ref = reference group.</p></fn><fn id="TFN3"><label>a</label><p id="P47">Results mutually adjusted for healthcare system in addition to all variables listed in table.</p></fn></table-wrap-foot></table-wrap><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Clinical practice points</title></caption><list list-type="bullet" id="L2"><list-item><p id="P48">The uptake of novel systemic treatment therapies occurs quickly as demonstrated in the rapid increase of IMO regimens after FDA approval</p></list-item><list-item><p id="P49">The use of targeted therapies as first-line therapy did not increase significantly over time</p></list-item><list-item><p id="P50">Despite the uptake of these new therapies, those at older ages continued to be less likely to receive systemic treatment compared to younger NSCLC patients.</p></list-item><list-item><p id="P51">We did not find an association between the receipt of systemic therapy and race, ethnicity, or SES.</p></list-item><list-item><p id="P52">The impact of these new therapies on real-world patient outcomes including quality of life, short- and long-term toxicities &#8211; including financial toxicities and survival need to be better understood.</p></list-item></list></boxed-text></floats-group></article></pmc-articleset>